Tapia, M.; Hernando, C.; Martínez, M.T.; Burgués, O.; Tebar-Sánchez, C.; Lameirinhas, A.; Ágreda-Roca, A.; Torres-Ruiz, S.; Garrido-Cano, I.; Lluch, A.;
et al. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies. Cancers 2023, 15, 4522.
https://doi.org/10.3390/cancers15184522
AMA Style
Tapia M, Hernando C, Martínez MT, Burgués O, Tebar-Sánchez C, Lameirinhas A, Ágreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A,
et al. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies. Cancers. 2023; 15(18):4522.
https://doi.org/10.3390/cancers15184522
Chicago/Turabian Style
Tapia, Marta, Cristina Hernando, María Teresa Martínez, Octavio Burgués, Cristina Tebar-Sánchez, Ana Lameirinhas, Anna Ágreda-Roca, Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lluch,
and et al. 2023. "Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies" Cancers 15, no. 18: 4522.
https://doi.org/10.3390/cancers15184522
APA Style
Tapia, M., Hernando, C., Martínez, M. T., Burgués, O., Tebar-Sánchez, C., Lameirinhas, A., Ágreda-Roca, A., Torres-Ruiz, S., Garrido-Cano, I., Lluch, A., Bermejo, B., & Eroles, P.
(2023). Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies. Cancers, 15(18), 4522.
https://doi.org/10.3390/cancers15184522
